ReviewBritish journal of pharmacology2013
Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?
Review in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality.Epilepsia · 2021Pooled it
- Probiotics and the Gut-Brain Axis: Emerging Therapeutic Strategies for Epilepsy and Depression Comorbidity.Foods (Basel, Switzerland) · 2025Review
- Strategic pathway analysis for dual management of epilepsy and comorbid depression: a systems biology perspective.In silico pharmacology · 2024Article
- Fenfluramine: a plethora of mechanisms?Frontiers in pharmacology · 2023Review
- Optimization of Therapy in Patients with Epilepsy and Psychiatric Comorbidities: Key Points.Current neuropharmacology · 2023Article
- Epilepsy Associated Depression: An Update on Current Scenario, Suggested Mechanisms, and Opportunities.Neurochemical research · 2021Review
- Risk Perceptions of Low Nicotine Cigarettes and Alternative Nicotine Products across Priority Smoking Populations.International journal of environmental research and public health · 2021Article
- Impact of Stress on Epilepsy: Focus on Neuroinflammation-A Mini Review.International journal of molecular sciences · 2021Review
- The Ketogenic Diet Revisited: Beyond Ketones.Frontiers in neurology · 2021Article
- Multipronged Attack of Stem Cell Therapy in Treating the Neurological and Neuropsychiatric Symptoms of Epilepsy.Frontiers in pharmacology · 2021Review
- An Unbiased Drug Screen for Seizure Suppressors in Duplication 15q Syndrome Reveals 5-HTBiological psychiatry · 2020Article
- The Gut-Brain-Axis on the Manifestation of Depressive Symptoms in Epilepsy: An Evidence-Driven Hypothesis.Frontiers in pharmacology · 2020Article
- The Progress in Diagnosis and Treatment of Exosomes and MicroRNAs on Epileptic Comorbidity Depression.Frontiers in psychiatry · 2020Review
- In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.International journal of molecular sciences · 2019Article
- Selective serotonin reuptake inhibitors and risk of epilepsy after traumatic brain injury - A population based cohort study.PloS one · 2019Article
- Antidepressant drug paroxetine blocks the open pore of Kv3.1 potassium channel.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2018Article
- Ferulic Acid Supplementation for Management of Depression in Epilepsy.Neurochemical research · 2017Article
- Recent advances in epilepsy.Journal of neurology · 2017Review
- Relative Safety of Different Antidepressants for Treatment of Depression in Chronic Epileptic Animals Associated with Depression.Journal of epilepsy research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a high incidence of psychiatric comorbidity in people with epilepsy (PWE), particularly depression. The manifold adverse consequences of comorbid depression have been more clearly mapped in recent years. Accordingly, considerable efforts have been made to improve detection and diagnosis, with the result that many PWE are treated with antidepressant drugs, medications with the potential to influence both epilepsy and depression. Exposure to older generations of antidepressants (notably tricyclic antidepressants and bupropion) can increase seizure frequency. However, a growing body of evidence suggests that newer ('second generation') antidepressants, such as selective serotonin reuptake inhibitors or serotonin-noradrenaline reuptake inhibitors, have markedly less effect on excitability and may lead to improvements in epilepsy severity. Although a great deal is known about how antidepressants affect excitability on short time scales in experimental models, little is known about the effects of chronic antidepressant exposure on the underlying processes subsumed under the term 'epileptogenesis': the progressive neurobiological processes by which the non-epileptic brain changes so that it generates spontaneous, recurrent seizures. This paper reviews the literature concerning the influences of antidepressants in PWE and in animal models. The second section describes neurobiological mechanisms implicated in both antidepressant actions and in epileptogenesis, highlighting potential substrates that may mediate any effects of antidepressants on the development and progression of epilepsy. Although much indirect evidence suggests the overall clinical effects of antidepressants on epilepsy itself are beneficial, there are reasons for caution and the need for further research, discussed in the concluding section.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.